Orion B Aktie

65,50 EUR -0,35 EUR -0,53 %

22:44:28

BMN

65,20 EUR -0,75 EUR -1,14 %

17:00:00

HEX

Orion B jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.9,28 Mrd. EUR

KGV18,22Div. Rendite3,83%

WKNA0J3QM

ISINFI0009014377

SymbolORINF

Orion B Aktien News

Sortieren:Datum Meistgelesen

24.02.25finanzen.netAusblick: Orion B legt die Bilanz zum abgelaufenen Quartal vor

24.02.25finanzen.netAusblick: Orion A zieht Bilanz zum jüngsten Jahresviertel

19.02.25GlobeNewswireOrion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

18.02.25GlobeNewswireOrion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

17.02.25GlobeNewswireOrion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

14.02.25GlobeNewswireOrion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

13.02.25GlobeNewswireEU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability

12.02.25GlobeNewswireOrion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

10.02.25GlobeNewswireSave the Date: Orion’s Capital Markets Day on 22 May 2025

10.02.25finanzen.netErste Schätzungen: Orion B mit Zahlen zum abgelaufenen Quartal

10.02.25finanzen.netErste Schätzungen: Orion A legt die Bilanz zum abgelaufenen Quartal vor

30.01.25GlobeNewswireOrion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

28.01.25GlobeNewswireOrion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

15.01.25GlobeNewswireInside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024

15.01.25GlobeNewswireRecommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting

13.01.25GlobeNewswire79,345 Orion Corporation A shares converted into B shares

07.01.25GlobeNewswireOrion’s collaboration partner Bayer submits application in China for third indication of darolutamide

30.12.24GlobeNewswireOrion and Marinus terminate agreement for ganaxolone in Europe

19.12.24GlobeNewswireCORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

19.12.24GlobeNewswireChange in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

18.12.24GlobeNewswireOrion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

12.12.24GlobeNewswirePenalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

27.11.24GlobeNewswire142,701 Orion Corporation A shares converted into B shares

22.11.24GlobeNewswireOrion Research Foundation grants EUR 1,109,000 for research in 2025

19.11.24GlobeNewswireOrion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

01.11.24GlobeNewswireOrion Corporation: Managers’ transactions – Henrik Stenqvist

01.11.24finanzen.netOrion B hat Bilanz für das abgelaufene Quartal gezogen

01.11.24finanzen.netOrion A: Bilanzzahlen zum vergangenen Quartal

29.10.24GlobeNewswireOrion Group Interim Report January–September 2024

24.10.24GlobeNewswireInside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

15.10.24GlobeNewswireOrion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

14.10.24GlobeNewswireOrion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14.10.24finanzen.netErste Schätzungen: Orion B informiert über die jüngsten Quartalsergebnisse

14.10.24finanzen.netErste Schätzungen: Orion A zieht Bilanz zum jüngsten Jahresviertel

30.09.24GlobeNewswireOrion’s near-term climate targets approved by the Science Based Targets initiative

26.09.24GlobeNewswireOrion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

20.09.24GlobeNewswire213,285 Orion Corporation A shares converted into B shares

11.09.24GlobeNewswireInside information: Orion upgrades full-year outlook for 2024

22.08.24GlobeNewswireOrion Corporation: Managers’ transactions – Satu Ahomäki

21.08.24GlobeNewswireOrion Corporation: Managers’ transactions – Niclas Lindstedt

Orion B News

Orion B News: auf dieser Seite finden Sie alle Orion B News und Nachrichten zur Orion B Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Orion B News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Orion B News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.